Evommune, Inc.

EVMN

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

RA Capital Management RTW Investments Eventide Asset Management

Position Trend

Feb 13, 2026

$16.5M

1 fund

Feb 17, 2026

$81.2M

2 funds

+393% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ARA Capital Management9.7%Feb 17, 2026

SC 13DRA Capital Management11.0%Nov 17, 2025

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 3,458,770Value: $59.2M

# Signal Note: RA Capital Initiates $59.2M Position in Evommune RA Capital's entry into EVMN signals conviction in the company's EVM201 program for systemic lupus erythematosus (SLE), a large autoimmune market with limited efficacy options. The $59.2M stake (representing ~3.5% ownership) aligns with RA's thesis on early-stage immunology; near-term catalysts include Phase 2 data readouts expected in 2024-2025. Kolchinsky's involvement suggests confidence in the underlying science, though investors should monitor cash runway and competitive positioning against established and emerging SLE therapies.

RTW InvestmentsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

WVE3 funds IRON3 funds BLTE3 funds SION2 funds TSHA2 funds PCSC2 funds RNA2 funds CAPR

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: RTW Investments Initiates $22M Position in Evommune RTW's entry into EVMN likely reflects conviction in the company's EVO-002 program (solid tumors with checkpoint inhibitor resistance), which is advancing through Phase 2 with near-term data catalysts expected in 2024-2025. The $22M stake (substantial for RTW's typical check sizes) suggests confidence in either clinical readout probability or partnership/M&A potential, though EVMN's pre-revenue status carries execution risk. Monitor upcoming 2024 clinical updates and any competitive positioning against larger IO-focused biotechs.